Table 1. Selected Pathways and Processes Targeted For Quantitative Assay Development.

Each cancer-related pathway or process is presented with its model cell line(s) used for generating protein for the LC-MRM screening and initial assay implementation. At least one assay has been developed or is currently under investigation to quantify the expression of each protein. Subsequent to the development of assays for expression, additional attention is paid to quantification of isoforms, truncations, mutations, and post-translational modifications of selected proteins.

Pathway/Process	Target Proteins, Peptides, (Assays)	Cancer	Cell Line(s) used for Development
Heat Shock Proteins	10, 36 (8)	Acute Myeloid Leukemia, Myeloma	U937, RPMI8226
BCR-Abl Signaling	7, 24 (11)	Chronic Myelogenous Leukemia	K562
Wnt Signaling	23, 87 (17)	Colon	HT29, HCT116, KM12, KM12C, KM12SM, KM12L4A, SW480, SW620
Notch Signaling	23, 37 (0)
TGF/SMAD/BMP Signaling	22, 44 (0)
Receptor Tyrosine Kinases (e.g., EGFR)/Substrates	23, 135 (9)	Lung, Melanoma, Colon, Breast	HCC827, H292, WM3670, WM3629, WM3130, HCT116, SKBR3, inter al.
Ras/Raf/Mek/Erk Signaling	11, 74 (0)	Melanoma	WM3670, WM3629, WM3130, inter al.
PI3K/AKT/MTOR Signaling	5, 45 (0)
Cyclins/Cyclin-dependent Kinases	4, 23 (0)
Apoptosis (Bcl-2 Family)	18, 30 (14)	Multiple Myeloma	RPMI8226, 8226/LR5
BRCA/Fanconi Anemia DNA Damage Response	13, 90 (13)
NFκB Signaling	3, 25 (8)
Other	59, 229 (23)	Myeloma, Breast, Bladder, Sarcoma, Melanoma, inter al.	Various Cells, Serum, Plasma, Urine